Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of Cizutamig for Patients with Ulcerative Colitis
NCT07353450Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cizutamig in ulcerative colitis (UC), sponsored by Ruijin Hospital. Primary endpoint: Safety and tolerability at 52 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
cizutamig
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07353450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353450.